OrbiMed Joins Loyal Valley, Qiming in Cell Therapy Platform
30 Apr 2026
US$ 20.00
OrbiMed Advisors LLC and Hankang Capital were party to the series A and series A+ financing rounds of Vivacta...
Related Publications
Subscribers’ Weekly for the week ending 1 May 2026...
Listen to Subscribers' Weekly 01 May 2026...
Connect With Us
We love to share Asia PE insights and news from time to time. Drop us your email address if you like to hear from us.
Rest assured that your email address will not be shared, as we hate spams as much as you do.